羟乙磺酸达尔西利片 | China Drugs ListDalpiciclib isethionate tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- HR阳性、HER2阴性乳腺癌：①与内分泌治疗联合，用于有高复发风险的早期乳腺癌辅助治疗；②与芳香化酶抑制剂联合，用于局部晚期或转移性乳腺癌的初始内分泌治疗；③与氟维司群联合，用于既往内分泌治疗后进展的局部晚期或转移性乳腺癌。For hormone receptor (HR)-positive, HER2-negative breast cancer: (1) with endocrine therapy as adjuvant treatment for early breast cancer at high risk of recurrence; (2) with an aromatase inhibitor as initial endocrine treatment for locally advanced or metastatic breast cancer; or (3) with fulvestrant for locally advanced or metastatic breast cancer that has progressed after previous endocrine therapy.
- 适应症来源与口径
- 2026-06-30
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。 生产商原始页面图像已按顺序保存。Complete official prescribing information obtained. Mainland China label. Original manufacturer page images have been preserved in order.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限：1.激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌患者；2.与芳香化酶抑制剂联合使用作为初始内分泌治疗；3.与氟维司群联合用于既往曾接受内分泌治疗后出现疾病进展的患者。Restricted to: (1) HR-positive, HER2-negative locally advanced or metastatic breast cancer; (2) use with an aromatase inhibitor as initial endocrine therapy; or (3) use with fulvestrant after progression on previous endocrine therapy.
- 医保期限
- 2025-01-01 至 2026-12-312025-01-01 to 2026-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.